Thomas Mcgauley Acquires 6,000 Shares of Tenax Therapeutics (NASDAQ:TENX) Stock

Tenax Therapeutics, Inc. (NASDAQ:TENX) CFO Thomas Mcgauley bought 6,000 shares of the company’s stock in a transaction on Monday, November 17th. The shares were bought at an average price of $7.25 per share, with a total value of $43,500.00. Following the completion of the transaction, the chief financial officer owned 5,000 shares of the company’s stock, valued at $36,250. The trade was a -600.00% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Thomas Mcgauley also recently made the following trade(s):

• On Monday, November 17th, Thomas Mcgauley purchased 2,000 shares of Tenax Therapeutics stock. The stock was bought at an average cost of $7.34 per share, with a total value of $14,680.00.

Tenax Therapeutics Trading Down 4.7%

Shares of NASDAQ:TENX traded down $0.36 during trading on Wednesday, reaching $7.32. The company had a trading volume of 34,510 shares, compared to its average volume of 44,900. The company has a fifty day moving average of $7.05 and a two-hundred day moving average of $6.32. The stock has a market capitalization of $33.40 million, a P/E ratio of -7.96 and a beta of 1.52. Tenax Therapeutics, Inc. has a 12 month low of $4.63 and a 12 month high of $8.24.

Tenax Therapeutics (NASDAQ:TENX) last announced its earnings results on Wednesday, November 12th. The specialty pharmaceutical company reported ($0.40) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.33) by $0.93. As a group, equities research analysts predict that Tenax Therapeutics, Inc. will post -0.88 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of TENX. Boothbay Fund Management LLC purchased a new stake in Tenax Therapeutics during the 3rd quarter valued at about $2,680,000. Woodline Partners LP purchased a new position in Tenax Therapeutics in the 3rd quarter worth approximately $671,000. Millennium Management LLC lifted its position in Tenax Therapeutics by 34.2% in the third quarter. Millennium Management LLC now owns 313,712 shares of the specialty pharmaceutical company’s stock valued at $2,387,000 after purchasing an additional 79,998 shares during the last quarter. ADAR1 Capital Management LLC boosted its stake in shares of Tenax Therapeutics by 98.1% during the first quarter. ADAR1 Capital Management LLC now owns 68,741 shares of the specialty pharmaceutical company’s stock valued at $450,000 after purchasing an additional 34,048 shares during the period. Finally, Citadel Advisors LLC boosted its stake in shares of Tenax Therapeutics by 318.1% during the third quarter. Citadel Advisors LLC now owns 43,253 shares of the specialty pharmaceutical company’s stock valued at $329,000 after purchasing an additional 32,908 shares during the period. 1.67% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on TENX shares. Wall Street Zen upgraded Tenax Therapeutics to a “sell” rating in a report on Saturday, October 25th. Weiss Ratings restated a “sell (d-)” rating on shares of Tenax Therapeutics in a research report on Tuesday, November 11th. Piper Sandler began coverage on Tenax Therapeutics in a research note on Monday, September 8th. They issued an “overweight” rating and a $20.00 target price for the company. Finally, Guggenheim cut their target price on Tenax Therapeutics from $15.00 to $14.00 and set a “buy” rating for the company in a research note on Thursday, August 14th. Three investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Tenax Therapeutics has an average rating of “Moderate Buy” and an average target price of $18.00.

About Tenax Therapeutics

Tenax Therapeutics, Inc develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.